Scholarlink

Background <p>Corticosteroids improve the outcomes of severe pneumonia; however, the most effective type remains unknown. In this study, we compared the mortality rates of patients with severe pneumonia who were treated with methylprednisolone versus those treated with hydrocortisone.</p> Methods <p>In this retrospective observational study, we utilized a nationwide Japanese Diagnosis Procedure Combination inpatient database to include adult patients with severe pneumonia who were admitted to hospitals between April 2017 and March 2022 and received either methylprednisolone or hydrocortisone. Propensity score matching was used to adjust for measured confounders, with in-hospital mortality as the primary outcome.</p> Results <p>Among the 5,084 eligible patients, 623 matched pairs were analyzed. In-hospital mortality rates were 23.9% in the hydrocortisone group and 19.4% in the methylprednisolone group (risk difference [RD], 4.5%; 95% confidence interval [CI] −0.082 to 9.1; p = 0.054). Subgroup analysis of patients with shock demonstrated significantly higher mortality in the hydrocortisone group than in the methylprednisolone group (44.7% versus 30.1%; RD, 14.6%; 95% CI 1.4–27.8; p = 0.031).</p> Conclusion <p>No significant difference in in-hospital mortality was observed between patients with severe pneumonia treated with methylprednisolone and those treated with hydrocortisone. Nevertheless, patients experiencing severe pneumonia-induced septic shock may derive benefits from methylprednisolone treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mortality of severe pneumonia treated with methylprednisolone versus hydrocortisone: a propensity-matched analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Takuya Sato,
  • Yusuke Sasabuchi,
  • Ryota Inokuchi,
  • Shotaro Aso,
  • Hideo Yasunaga,
  • Kent Doi

摘要

Background

Corticosteroids improve the outcomes of severe pneumonia; however, the most effective type remains unknown. In this study, we compared the mortality rates of patients with severe pneumonia who were treated with methylprednisolone versus those treated with hydrocortisone.

Methods

In this retrospective observational study, we utilized a nationwide Japanese Diagnosis Procedure Combination inpatient database to include adult patients with severe pneumonia who were admitted to hospitals between April 2017 and March 2022 and received either methylprednisolone or hydrocortisone. Propensity score matching was used to adjust for measured confounders, with in-hospital mortality as the primary outcome.

Results

Among the 5,084 eligible patients, 623 matched pairs were analyzed. In-hospital mortality rates were 23.9% in the hydrocortisone group and 19.4% in the methylprednisolone group (risk difference [RD], 4.5%; 95% confidence interval [CI] −0.082 to 9.1; p = 0.054). Subgroup analysis of patients with shock demonstrated significantly higher mortality in the hydrocortisone group than in the methylprednisolone group (44.7% versus 30.1%; RD, 14.6%; 95% CI 1.4–27.8; p = 0.031).

Conclusion

No significant difference in in-hospital mortality was observed between patients with severe pneumonia treated with methylprednisolone and those treated with hydrocortisone. Nevertheless, patients experiencing severe pneumonia-induced septic shock may derive benefits from methylprednisolone treatment.